Opposite roles of FOXA1 and NKX2‐1 in lung cancer progression

Gene copy number profiles of primary lung tumors were screened for high‐level amplifications. We detected 22 high‐level amplifications in various loci, including 14q13. This locus is known to harbor the adenocarcinoma (AC) lineage‐specific target gene NKX2‐1, which is not expressed in squamous cell carcinoma (SCC). As the 14q amplification was also found in SCC, we investigated whether or not FOXA1 might be the corresponding target gene for SCC. Focusing on these two target genes, we assessed gene amplifications and protein expression of NKX2‐1 and FOXA1 in primary lung tumors (n = 554) and brain metastases (n = 68). Primary AC (n = 194) showed positive protein expression of NKX2‐1 in 58.2% of the samples compared with 4.2% of primary SCC samples (n = 212). Positive staining for FOXA1 was seen in 34.7% of the SCC samples, which was comparable with 39.6% in the AC samples. For brain metastases, FOXA1 expression was slightly higher in the SCC samples (55.6%) compared with the non‐matched primary SCC tumor samples (43.4%), whereas NKX2‐1 expression was comparable in both primary tumors and brain metastases. Positive FOXA1 and NKX2‐1 expression was associated with a gain or amplification in 34.6% and 28.6% of cases, respectively. The expression of NKX2‐1 was associated with early stage and grade among the AC cases. In contrast, FOXA1 expression in SCC was associated with distant metastases as well as an unfavorable survival rate (P = 0.039). These results suggest that both FOXA1 and NKX2‐1 may act as lineage‐specific target genes within the 14q amplicon with opposite functions in lung cancer. © 2012 Wiley Periodicals, Inc.

[1]  Samuel Leung,et al.  FOXA1 is an independent prognostic marker for ER-positive breast cancer , 2012, Breast Cancer Research and Treatment.

[2]  S. Badve,et al.  High‐level expression of forkhead‐box protein A1 in metastatic prostate cancer , 2011, Histopathology.

[3]  Derek Y. Chiang,et al.  Suppression of Lung Adenocarcinoma Progression by Nkx2-1 , 2011, Nature.

[4]  Humam Kadara,et al.  Abnormalities of the TITF-1 Lineage-Specific Oncogene in NSCLC: Implications in Lung Cancer Pathogenesis and Prognosis , 2011, Clinical Cancer Research.

[5]  Thomas M. Harris,et al.  Both Gene Amplification and Allelic Loss Occur at 14q13.3 in Lung Cancer , 2010, Clinical Cancer Research.

[6]  M. Washington,et al.  Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. , 2010, Cancer research.

[7]  M. Loda,et al.  FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma , 2009, Clinical Cancer Research.

[8]  H. Dressman,et al.  Characterizing the developmental pathways TTF-1, NKX2–8, and PAX9 in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[9]  B. Ylstra,et al.  Genomic Profiles Associated with Early Micrometastasis in Lung Cancer: Relevance of 4q Deletion , 2009, Clinical Cancer Research.

[10]  G. Bepler,et al.  Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Meyerson,et al.  TTF1 expression in non‐small cell lung carcinoma: association with TTF1 gene amplification and improved survival , 2009, The Journal of pathology.

[12]  V. Boggaram.  Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. , 2009, Clinical science.

[13]  R. Herbst,et al.  Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I Petersen,et al.  Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer , 2008, Oncogene.

[15]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[16]  J. Jagirdar.  Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. , 2008, Archives of pathology & laboratory medicine.

[17]  M. Baudis.  Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data , 2007, BMC Cancer.

[18]  Derek Y. Chiang,et al.  Characterizing the cancer genome in lung adenocarcinoma , 2007, Nature.

[19]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[20]  M. Moasser.  Targeting the function of the HER2 oncogene in human cancer therapeutics , 2007, Oncogene.

[21]  N. Thatcher,et al.  Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics. , 2007, Lung Cancer.

[22]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[23]  Y. Yatabe,et al.  Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. , 2007, Cancer research.

[24]  Hongyan Chen,et al.  Physical and Functional Interactions between Homeodomain NKX2.1 and Winged Helix/Forkhead FOXA1 in Lung Epithelial Cells , 2007, Molecular and Cellular Biology.

[25]  Matthew J Hayat,et al.  Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. , 2007, The oncologist.

[26]  J. Lafitte,et al.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K. Kaestner,et al.  The Foxa family of transcription factors in development and metabolism , 2006, Cellular and Molecular Life Sciences CMLS.

[28]  S. Chin,et al.  Human and mouse oligonucleotide-based array CGH , 2005, Nucleic acids research.

[29]  B. Chetaille,et al.  Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung , 2005, British Journal of Cancer.

[30]  Jeffrey A Whitsett,et al.  Compensatory Roles of Foxa1 and Foxa2 during Lung Morphogenesis* , 2005, Journal of Biological Chemistry.

[31]  S. Knuutila,et al.  CDK4 is a probable target gene in a novel amplicon at 12q13.3–q14.1 in lung cancer , 2005, Genes, chromosomes & cancer.

[32]  Elena Marchiori,et al.  Breakpoint identification and smoothing of array comparative genomic hybridization data , 2004, Bioinform..

[33]  J. Whitsett,et al.  Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. , 2004, Gene expression patterns : GEP.

[34]  A Coldman,et al.  Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers , 2004, The Journal of pathology.

[35]  K. Kerr,et al.  Thyroid transcription factor 1 in pulmonary adenocarcinoma , 2004, Journal of Clinical Pathology.

[36]  Klaus Pantel,et al.  Molecular signature associated with bone marrow micrometastasis in human breast cancer. , 2003, Cancer research.

[37]  Susan E Wert,et al.  TTF-1 Phosphorylation Is Required for Peripheral Lung Morphogenesis, Perinatal Survival, and Tissue-specific Gene Expression* , 2003, Journal of Biological Chemistry.

[38]  David E. Misek,et al.  The Hepatocyte Nuclear Factor 3 α Gene, HNF3α (FOXA1), on Chromosome Band 14q13 Is Amplified and Overexpressed in Esophageal and Lung Adenocarcinomas , 2002 .

[39]  Y. Yatabe.  9 - Role of Thyroid Transcription Factor-1 in Pulmonary Adenocarcinoma , 2002 .

[40]  David E. Misek,et al.  The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. , 2002, Cancer research.

[41]  M. Zakowski,et al.  Use of thyroid transcription factor 1, PE‐10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine‐needle aspiration biopsy specimens , 2001, Cancer.

[42]  R. Dziadziuszko,et al.  Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. , 2000, The Journal of thoracic and cardiovascular surgery.

[43]  L. Lim,et al.  Thyroid transcription factor-1, hepatocyte nuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing mouse lung. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.